bezafibrate

Ligand id: 2668

Name: bezafibrate

IUPHAR Pharmacology Education Project (PEP) logo

View more information in the IUPHAR Pharmacology Education Project: bezafibrate

Structure and Physico-chemical Properties

2D Structure
Calculated Physico-chemical Properties
Hydrogen bond acceptors 4
Hydrogen bond donors 2
Rotatable bonds 8
Topological polar surface area 75.63
Molecular weight 361.11
XLogP 4.13
No. Lipinski's rules broken 0

Molecular properties generated using the CDK

No information available.
Summary of Clinical Use
Used to treat hyperlipidaemia. It helps to lower LDL cholesterol and triglyceride levels in the blood, and increases HDL. Not approved by the US FDA. In the EU, the EMA's Committee for Medicinal Products for Human Use (CHMP) has recommended that fibrates should be used only when statins are contra-indicated or are not tolerated. Other national approval agencies may have authorised marketing of this drug.
Mechanism Of Action and Pharmacodynamic Effects
Bezafibrate is predominantly an agonist of PPARα but may have some activity at PPARγ and PPARδ.